Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aptevo Therapeutics Inc (APVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Research Report Identifies Fastenal, Ideal Power, Fuel Tech, CTI BioPharma, Aptevo Therapeutics, and Caseys General Stores with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fastenal Company (NASDAQ:FAST),...

IPWR : 0.50 (-6.52%)
CTIC : 1.01 (+5.76%)
FTEK : 2.66 (+8.57%)
APVO : 0.79 (-0.75%)
CASY : 132.98 (+0.74%)
FAST : 71.10 (+1.43%)
Aptevo Therapeutics Reports IXINITY(R) and Pipeline Progress

Reports 73% Increase in IXINITY Year-Over-Year Quarterly Net Revenue in Q1 2019

APVO : 0.79 (-0.75%)
Aptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting

APVO436 Preclinical Data Continue to Show Promising Results Supporting Clinical Development for the Treatment of Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS) and Differentiation...

APVO : 0.79 (-0.75%)
Aptevo Therapeutics to Present New Preclinical Data for APVO436 and ALG.APV.527 at the American Association for Cancer Research 2019 Annual Meeting

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that preclinical data for two of its ADAPTIR(TM)...

APVO : 0.79 (-0.75%)
Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases

Unique Mechanism of Action Suppresses Inflammation and Immune Activation Without Promoting Pro-Inflammatory Lymphocyte Stimulation

APVO : 0.79 (-0.75%)
Aptevo Therapeutics Reports 2018 Financial Results and Provides Business Update

Achieves Record Annual IXINITY Net Revenue of $23.1 Million Representing 111% Increase Over 2017

APVO : 0.79 (-0.75%)
Aptevo Therapeutics Inc. (APVO) Moves to Buy: Rationale Behind the Upgrade

Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

APVO : 0.79 (-0.75%)
Aptevo Announces Pricing of $22 Million Offering of Common Stock and Warrants

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced the pricing of (i) for a combined public offering...

APVO : 0.79 (-0.75%)
Aptevo Announces Proposed Public Offering of Common Stock and Warrants

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that it intends to offer and sell, subject...

APVO : 0.79 (-0.75%)
Aptevo Therapeutics Highlights Key 2019 Priorities

ADAPTIR(TM) Bispecific Antibody Candidates Poised to Progress in Clinical Development

APVO : 0.79 (-0.75%)
Aptevo Therapeutics Collects $3.3 Million In Escrow Funds From Saol Therapeutics

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it has collected $3.3 million in escrow funds from...

APVO : 0.79 (-0.75%)
Aptevo Therapeutics Announces Up To $35 Million Common Stock Purchase Agreement With Lincoln Park Capital

Provides Opportunistic Capital of up to $35 Million to Aptevo During the 36-month Term of the Agreement

APVO : 0.79 (-0.75%)
Wired News - Arrowhead Pharma Presented Preclinical Data on Expanding Pipeline of RNAi Therapeutics for Cardiometabolic Diseases

Stock Monitor: Aptevo Therapeutics Post Earnings Reporting

ARWR : 19.07 (+2.91%)
APVO : 0.79 (-0.75%)
Aptevo Therapeutics Reports First Quarter 2018 Financial Results

Almost Doubles Year-Over-Year IXINITY Quarterly Revenue

APVO : 0.79 (-0.75%)
New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Aptevo Therapeutics and Alligator Bioscience at Prominent Industry Conferences

ALG.APV-527 is Designed to Strategically Target and Engage the Immune System for the Potential Treatment of Multiple Solid Tumor Indications

APVO : 0.79 (-0.75%)
What's in Store for Horizon Pharma (HZNP) in Q1 Earnings?

On Horizon Pharma's (HZNP) first-quarter 2018 earnings call, investors focus will be on the performance of its business units and key products.

ADVM : 6.61 (+2.96%)
HZNP : 25.26 (+2.98%)
APVO : 0.79 (-0.75%)
CLVS : 20.83 (+2.51%)
What's in the Cards for Inovio (INO) This Earnings Season?

Inovio's (INO) most advanced pipeline candidate, VGX-3100's progress remains in focus. However, lack of an approved product in the company's portfolio is a dampener.

ADVM : 6.61 (+2.96%)
ARRY : 22.92 (+2.69%)
APVO : 0.79 (-0.75%)
INO : 3.86 (+1.58%)
What's in Store for Celldex (CLDX) This Earnings Season?

With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on its immuno-oncology pipeline.

CLDX : 3.97 (+9.67%)
ARRY : 22.92 (+2.69%)
APVO : 0.79 (-0.75%)
BMY : 45.32 (+0.18%)
What's in the Cards for Geron (GERN) This Earnings Season?

With no approved product in Geron's (GERN) portfolio, investor focus continues to remain on its sole pipeline candidate, imetelstat, ahead of the first-quarter earnings release.

ARRY : 22.92 (+2.69%)
APVO : 0.79 (-0.75%)
JNJ : 139.90 (+1.50%)
GERN : 1.92 (unch)
What's in the Cards for Merrimack (MACK) in Q1 Earnings?

Investor focus is likely to remain on Merrimack's (MACK) pipeline updates when it reports first-quarter numbers.

ADVM : 6.61 (+2.96%)
ARRY : 22.92 (+2.69%)
APVO : 0.79 (-0.75%)
MACK : 6.08 (-1.78%)

Van Meerten Stock Picks

Aaon - Pick of the Day
My Stock Pick of the Day is the HVAC company AAON (AAON).
AAON +1.04
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar